×
Ocular Therapeutix EBITDA 2013-2024 | OCUL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ocular Therapeutix ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Ocular Therapeutix EBITDA 2013-2024 | OCUL
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Ocular Therapeutix ebitda from 2013 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$89B
Takeda Pharmaceutical (TAK)
$47.2B
Merck (MKGAF)
$23.7B
Astellas Pharma (ALPMY)
$22.1B
Summit Therapeutics (SMMT)
$17.8B
Sandoz Group AG (SDZNY)
$17.6B
United Therapeutics (UTHR)
$15.2B
Shionogi (SGIOY)
$13.1B
Neurocrine Biosciences (NBIX)
$12.1B
Catalent (CTLT)
$10.9B
Orion OYJ (ORINY)
$7.4B
Revolution Medicines (RVMD)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.1B
Corcept Therapeutics (CORT)
$4.4B
Crinetics Pharmaceuticals (CRNX)
$4.2B
Dyne Therapeutics (DYN)
$3.4B
PTC Therapeutics (PTCT)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.4B
Soleno Therapeutics (SLNO)
$2.1B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.6B
Xencor (XNCR)
$1.6B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B